Related Experiment Video

Updated: Mar 9, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Thrombosis Related ABO, F5, MTHFR, and FGG Gene Polymorphisms in Morbidly Obese Patients

Kristina Kupcinskiene1, Martyna Murnikovaite2, Greta Varkalaite2

  • 1Department of Anesthesiology, Lithuanian University of Health Sciences, Eiveniu Str. 2, LT-50009 Kaunas, Lithuania.

Disease Markers
|December 22, 2016
PubMed

Insights

This study investigated thrombosis-related gene polymorphisms in morbidly obese patients. Key gene variants, including MTHFR, were not significantly associated with morbid obesity or related traits in European subjects.

Area of Science:

  • Genetics
  • Obesity Research
  • Thrombosis

Background:

  • Obesity is a significant risk factor for thrombotic complications.
  • Understanding the genetic predisposition to thrombosis in obesity is crucial for risk stratification and management.
  • Specific gene polymorphisms in ABO, F5, MTHFR, and FGG have been implicated in thrombotic events.

Purpose of the Study:

  • To determine the frequency of specific thrombosis-related gene polymorphisms (ABO, F5, MTHFR, FGG) in morbidly obese patients.
  • To compare the distribution of these gene polymorphisms between morbidly obese individuals and nonobese controls.
  • To assess the association of these polymorphisms with anthropometric measures like height and weight in the studied populations.

Main Methods:

  • Genotyping of single nucleotide polymorphisms (SNPs) in ABO (rs505922), F5 (rs6427196), MTHFR (rs1801133), and FGG (rs6536024) was performed using RT-PCR.
  • The study included 320 morbidly obese patients (BMI > 40 kg/m²) and 303 nonobese control individuals (BMI < 30 kg/m²).
  • All participants were of European descent.

Main Results:

  • No significant differences were observed in the overall distribution of genotypes and alleles for the studied SNPs between morbidly obese and nonobese groups.
  • A non-significant tendency was noted for the MTHFR rs1801133 TT genotype to be linked with morbid obesity (OR 1.84, P=0.129).
  • The distribution of height and weight means did not significantly differ among individuals carrying different genotypes of the investigated SNPs.

Conclusions:

  • The investigated gene polymorphisms (ABO C>T, F5 C>G, MTHFR C>T, FGG C>T) were not found to be associated with morbid obesity in the European cohort studied.
  • These specific genetic variations do not appear to be significant risk factors for height, weight, or morbid obesity in this population.
  • Further research may be needed to explore other genetic or environmental factors contributing to thrombosis risk in obese individuals.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta11:44

A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta

Published on: September 27, 2017

11.9K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
336
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
321